How to Best Enable Pharma Innovation Beyond the COVID-19 Crisis
May 26, 2020
Innovating in response to public health challenges like COVID-19 does not always align well with pharmaceutical industry commercial models or shareholder expectations. More sustainable and scalable ways of incentivizing innovation in response to infectious disease threats are needed.